Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31220020 | 1.00 | NOTUM (0.71) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL28767800 | 0.86 | NOTUM (0.73) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL27489322 | 0.86 | NOTUM (0.56) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL8489445 | 0.84 | PDE5A (0.68) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL29850056 | 0.83 | NOTUM (1.00) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL30600284 | 0.83 | MEN1 (0.54) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL6251744 | 0.83 | NOTUM (0.69) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL8733182 | 0.83 | MEN1 (0.54) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL1304374 | 0.83 | NOTUM (1.00) | NOTUMHPGDMEN1KMT2AKDM4E | |
| SCHEMBL5682752 | 0.80 | NPC1 (0.70) | NOTUMHPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110423212-B | Hydroxy indole carboxylic acid-based inhibitors of SHP2 | 美国印第安纳大学研究和技术公司 | 2023-05-09 | — | — | CN | claimed |
| CN-105142634-B | Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2(SHP2) comprising Src homology-2domain | 美国印第安纳大学研究和技术公司 | 2020-06-12 | — | — | CN | claimed |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
| CN-110423212-B | Hydroxy indole carboxylic acid-based inhibitors of SHP2 | 美国印第安纳大学研究和技术公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-105142634-B | Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2(SHP2) comprising Src homology-2domain | 美国印第安纳大学研究和技术公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-105142634-B | Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2(SHP2) comprising Src homology-2domain | 美国印第安纳大学研究和技术公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-105142634-B | Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2(SHP2) comprising Src homology-2domain | 美国印第安纳大学研究和技术公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2016131789-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-25 | — | — | WO | disclosed |
| EP-3056202-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-17 | — | — | EP | disclosed |
| CN-103328478-B | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-07 | — | — | CN | disclosed |
| EP-2654421-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | disclosed |
| CN-103328478-A | Piperidinone carboxamide azaindane cgrp receptor antagonists | MERCK SHARP & DOHME | 2013-09-25 | — | — | CN | disclosed |
| WO-2012087777-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-7214700-B2 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1299355-A2 | (2-OXINDOL-3-YLIDENYL)ACETIC ACID DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001083450-A2 | (2-OXINDOL-3-YLIDENYL)ACETIC ACID DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | NOTUM 3421/4885HPGD 559/4885MEN1 4217/4885 |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | NOTUM 3421/4885HPGD 559/4885MEN1 4217/4885 |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | NOTUM 3421/4885HPGD 559/4885MEN1 4217/4885 |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | NOTUM 2168/4885HPGD 198/4885MEN1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.